Liquidia Corp
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
LQDA$51.40+7.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The exhibits listed on the Exhibit Index hereto are filed or furnished (as stated therein) as part of this Quarterly Report on Form 10-Q.
| Exhibit No. | | Document |
| 10.1++ | | Settlement Agreement, dated October 13, 2026, by and between Liquidia Technologies, Inc. and UnitedTherapeutics Corporation (incorporated herein by reference to Exhibit 10.1 to the Company’s CurrentReport on Form 8-K, filed with the SEC on October 14, 2026). |
| 10.2++ | | Settlement and Termination Agreement, dated October 11, 2026, by and between Liquidia Technologies,Inc. and Sandoz Inc. (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Reporton Form 8-K, filed with the SEC on October 14, 2026). |
| 10.3++ | | Settlement and Termination Agreement, dated October 8, 2026, by and among Liquidia PAH, LLC,Liquidia Technologies, Inc. and Henderson SPV, LLC (incorporated herein by reference to Exhibit 10.3to the Company’s Current Report on Form 8-K, filed with the SEC on October 14, 2026). |
| 10.4++ | | Settlement and Termination Agreement, dated October 10, 2026, by and among Liquidia PAH, LLC,Liquidia Technologies, Inc. and PBM RG Holdings, LLC (incorporated herein by reference to Exhibit10.4 to the Company’s Current Report on Form 8-K, filed with the SEC on October 14, 2026). |
| 10.5++ | | Seventh Amendment to Revenue Interest Financing Agreement, dated October 13, 2026, by and betweenLiquidia Technologies, Inc. and HealthCare Royalty Partners IV, L.P. (incorporated herein by referenceto Exhibit 10.5 to the Company’s Current Report on Form 8-K, filed with the SEC on October 14, 2026). |
| 10.6*++ | | Form of Irrevocable Standby Letters of Credit, dated October 23, 2026, issued by JPMorgan Chase Bank, N.A. in favor of United Therapeutics Corporation for the Account of Liquidia Technologies, Inc. |
| 31.1* | | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act. |
| 31.2* | | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act. |
| 32.1** | | Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act. |
| 32.2** | | Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act. |
| 101.INS* | | Inline XBRL Instance Document |
| 101.SCH* | | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL* | | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF* | | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB* | | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE* | | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104* | | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101). |
*Filed herewith.
**Furnished herewith.
| ++ | Portions of this exhibit have been redacted because the company has determined that the redacted information is not material and is the type that the Company treats as private or confidential. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.